skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

ファーマインテリジェンスはInforma PLCのインフォーマインテリジェンス部門の一部です

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon レポートストアメルマガ登録製品ログインProductLogin
Global Search Configuration
  • Close Icon

ジェネリック医薬品、バイオシミラーの情報源として

Generics_Bulletin2

日本国内では2020年9月までにジェネリック医薬品の使用割合を80％にする目標を挙げています。このような中、Generics Bulletinはグローバルな専門アナリスト＆ジャーナリストの広範なネットワークを駆使して、世界中の市場動向を追跡することで、貴重なニュースを提供しています。また、市場プレーヤーのトップエグゼクティブやオピニオンリーダーのインタビューなども定期的に掲載しています。

深い専門性と具体的なデータに基づいたニュースレポートは、世界の大手ジェネリック医薬品メーカーの戦略を明らかにし、その計画、ポートフォリオ、業績を分析＆報告します。

Generics Bulletinでは以下のトピックをカバーしています。

  • 規制・コンプライアンスの変更
  • 法規制の進展
  • 競合製品の開発
  • 合併・買収活動
  • 新製品の発売
  • マーケティングの課題
  • 広告戦略など
無料トライアル申込

このサービスの特徴

世界のジェネリック＆ バイオシミラーを把握

Generics Bulletinの専属ジャーナリストが、ジェネリック医薬品（後発医薬品）、バイオシミラー（バイオ後続品）、付加価値医薬品産業について詳しくお伝えします。

国際競争力を強化する独自のニュースと分析

正確なデータと現地市場のタイムリーな分析により、事実の報道ではない御社の競争力強化に繋がるジェネリック医薬品とバイオシミラー市場の情報をお届けします。

オンラインでアクセスできるから簡単＆便利

スマホ、タブレット、PCなどあらゆるデバイスから記事にアクセスできます。関心のあるニュースやトピックを常に把握できるようにコンテンツのカスタマイズも可能。
ask the expert

ジャーナリスト＆アナ リストがご質問に回答

ニュースや記事の内容又はデータや分析に関してご質問がございましたらお気軽にご連絡下さい。Generics Bulletinのジャーナリストまたはアナリストがお答えします。

無料の最新記事＆レポート

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Celltrion Sets Out Plans To Trial Coronavirus Treatments

    In an exclusive interview with Generics Bulletin, Celltrion Healthcare’s UK commercial director, Matt Eddleston, has set out the firm’s plans to roll out an antibody test and trial two antiviral treatments for COVID-19. Meanwhile, the company’s recently-launched subcutaneous version of biosimilar infliximab, Remsima SC, is helping to free up hospital space in the UK by allowing treatment to be moved out of that setting as the coronavirus pandemic progresses.

    Topic Coronavirus

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Biosimilars Conference Coverage

    Biosimilars Conference Coverage

    Industry analysts from Generics Bulletin are bringing you free insights from their comprehensive biosimilars coverage. Obtain critical industry information covering new biosimilars launches, company strategies, and new biosimilars product development.

    Topic biosimilars

    Single report

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Celltrion Will Trial COVID-19 Antiviral From July

    Celltrion has made progress in finding an effective treatment for COVID-19 by identifying 14 antibodies able to neutralize coronavirus. The company aims to eventually roll out mass production of a therapeutic antibody treatment after starting human trials this July.

    Topic Coronavirus vaccines

    View article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Australian Bodies Set Out Joint Position On Coronavirus

    Australia’s off-patent industry association, the GBMA, and local brand organization Medicines Australia have set out their plans for collaborating on supplying essential medicines amid the coronavirus pandemic.

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Coronavirus Puts The Brakes On Mylan-Upjohn Merger

    Mylan and Pfizer’s Upjohn were all set to merge into Viatris by midway through this year, subject to certain approvals, but that will now not happen in that timeframe as the global coronavirus pandemic proves an insurmountable barrier to getting the deal over the line.  

    Topic Coronavirus

    View article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Australia Relaxes Competition Rules To Facilitate Coronavirus Response

    Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.

    Topic Coronavirus

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Celltrion Makes Progress On Coronavirus Treatment

    Coronavirus_Elbow_pump

    Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.

    Topic Coronavirus

    article

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Trialtrove: 医療用医薬品の臨床試験情報デ...

    COVID-19 Infographic

    COVID-19 Infographic

    Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.

    Topic Coronavirus

    View infographic

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Sandoz, Teva And Mylan Step Up On Hydroxychloroquine

    To meet expected demand in the weeks and months ahead, Novartis' Sandoz has committed to donate up to 130 million doses of generic hydroxychloroquine – a treatment for malaria currently under investigation as a therapy to aid in the COVID-19 pandemic – while Teva and Mylan have also made strides, as the generics industry continues to play its part in tackling the coronavirus outbreak.

    Topic Coronavirus

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Preserving Full Capacity Is Key To Global Coronavirus Reponse

    Leaders around the world must do all they can to ensure that medicines manufacturing and the supply chain are operating at full capacity as part of efforts to tackle the coronavirus outbreak, global off-patent industry association the IGBA has urged.

    Topic Coronavirus

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Celltrion Pledges Efforts on Coronavirus Antibody And Kit

    Celltrion unveils emergency plans to deal with the COVID-19 situation in South Korea by speeding up development of a potential therapeutic antibody and rapid, accurate testing kit without considering economic returns.

    Topic Coronavirus

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Green Lanes Will Help EU Fight Coronavirus

    Industry has welcomed the European Commission’s introduction of priority freight lanes, or ‘green lanes’, for essential goods to help address the challenges posed by the coronavirus outbreak.

    Topic Coronavirus

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    European Coronavirus Planning Requires ‘Structured Dialog’

    European off-patent industry association Medicines for Europe has called on the European Commission to urgently establish a “structured dialog” involving industry stakeholders, to help plan for an extended outbreak of coronavirus.

    Topic Coronavirus

    View article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Sun Finds US ‘Challenging’

    Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.

    Topic deal-trends

    article

  • Generics Bulletin: ジェネリック＆バイオシミラーニュース

    Who’s Hired? Sandoz Germany Seeks A New Country Head

    While Sandoz looks for a new country head in Germany, Lupin has appointed a new chief corporate development officer and a Coherus executive has left the firm.

    Topic business-strategies

    View article

医薬品産業専門のジャーナリスト＆アナリスト

Editor

Aidan Fry

Editor, Executive Editor, Commercial/R&D

UK

Aidan Fry

Aidan specializes in

  • Biosimilars
  • Generics
  • Legal Issues And Intellectual Property
  • Market intelligence

+22 year(s) experience

Profile
Consultant

Duncan Emerton

Consultant, Director Pharma Consulting

UK

Duncan Emerton

Duncan specializes in

  • Commercial Strategy
  • Biosimilars
  • Generics

+20 year(s) experience

Profile
Editor

Andrea Charles

Editor, Editor, Custom Content

UK

Andrea Charles

Andrea specializes in

  • Biosimilars
  • Biotech
  • Commercial Strategy
  • Generics
  • Clinical Trials

+17 year(s) experience

Profile
See all analysts

無料トライアル＆お問い合わせ

ニュースサービスでは無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。
Request a free trial

ご質問等ございましたらお気軽にご連絡下さい。

日本（平日：9時～18時）
電話：+81 (0)3 6273 4260
Email：inquiry.jp@informa.com

General enquiry

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。

レポートストア